Chronic hand eczema and hepatogenic pruritus with good response to apremilast

Hand eczema (HE) presents a high prevalence and severe impact on the quality of life of the patients. HE is a worldwide problem recognized for his high socio‐occupational involvement. Treatment is mainly based on adequate recommendations for hand care together with topical anti‐inflammatory treatments. Frequently, patients require systemic treatments such alitretinoin, among others. The comorbidities of the patients and the side effects of the treatments sometimes require prescribing other treatments off label on the technical data. This role in immunomodulation has led to the development of new studies that investigate what role does apremilast have in eczematous diseases, such as atopic dermatitis. We present this case for the quick and complete response of HE with apremilast, and the effective control of hepatogenic pruritus. These finding open a new possibility and alternative treatment of this complex and difficult of control with the treatments already described in the literature.

[1]  Ahmad Settin,et al.  The effectiveness of alitretinoin for the treatment of chronic hand eczema: A meta-analysis , 2018, International journal of health sciences.

[2]  L. Naldi,et al.  Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data , 2018, The British journal of dermatology.

[3]  W. Liao,et al.  Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses , 2017, Journal of the American Academy of Dermatology.

[4]  Hyun-Joo Lee,et al.  Acitretin as a Therapeutic Option for Chronic Hand Eczema , 2017, Annals of dermatology.

[5]  S. Tubeuf,et al.  Treatment of severe, chronic hand eczema: results from a UK‐wide survey , 2017, Clinical and experimental dermatology.

[6]  L. Scott,et al.  Alitretinoin: A Review in Severe Chronic Hand Eczema , 2016, Drugs.

[7]  D. Cohen,et al.  Usage and Distribution for Commercial Purposes Requires Written Permission. Apremilast Use for Moderate-to- Severe Atopic Dermatitis in Pediatric Patients Saporito and Cohen: Apremilast Use for Moderate-to-severe Atopic Dermatitis in Pediatric Patients , 2022 .

[8]  P. Elsner,et al.  Hand Dermatitis: A Review of Clinical Features, Prevention and Treatment , 2015, American Journal of Clinical Dermatology.

[9]  T. Agner,et al.  Guidelines for diagnosis, prevention and treatment of hand eczema , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  M. Wittmann,et al.  Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases , 2013, Dermatology and Therapy.

[11]  E. Simpson,et al.  A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. , 2012, Archives of dermatology.